MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, with its lead asset ateganosine, an investigational small molecule that targets telomerase-positive cancer cells by incorporating into telomeres to cause cancer cell death while simultaneously activating anti-tumor immune responses. The company is advancing ateganosine through multiple clinical programs in non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and small cell lung cancer, typically in combination with checkpoint inhibitors licensed from partners such as Regeneron, BeiGene (now BeOne Medicines), and Roche. MAIA currently operates as a clinical-stage company with no product revenues, but maintains partnerships that provide clinical supply cost savings and has secured exclusive worldwide rights to telomere-targeting technology from the University of Texas Southwestern Medical Center.